Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Government must have...

    Government must have compulsive licensing for essential drugs : Chairman, Cipla

    Farhat NasimWritten by Farhat Nasim Published On 2019-03-08T09:30:48+05:30  |  Updated On 16 Aug 2021 11:31 AM IST

    Cipla Chairman, Y K Hamied said that many drugs which are not covered under patent should be made in India which is not happening at present, citing the example of Vitamin B12, Vitamin B6, Vitamin D, Vitamin C.


    New Delhi: The Government needs to have a compulsive licensing system for essential drugs and look at locally manufacturing non-patented medicines, Cipla chairman Y K Hamied said Wednesday.


    "For healthcare what India requires is a pragmatic compulsive licensing system. My own reading is what the government should do is to formalise what are the drugs that are the priority for India, which we Indians can't do (produce). A big example is a drug for TB (Bedaquiline)," he said.


    Read Also: Cipla to acquire 11.71 percent stake in Wellthy Therapeutics


    "If India requires something, the government should ask such foreign companies give us your products and we are willing to pay you a royalty...Those drugs which are essential to India, the government should step in and ask for a voluntary license and give a royalty," he added.


    The industry doyen pointed out that 70 per cent of the major drugs are in-licensed and it is what India should look to do.


    "It is what India should ask, in-license and pay the royalty. Science has to be rewarded not denied particularly in a country like ours with 1.35 billion people, you cannot afford a monopoly. I have never been against patents, I have been against monopoly," he said.


    Read Also: Cipla gets USFDA nod for Medroxyprogesterone injectable


    He added that many drugs which are not covered under patent should be made in India which is not happening at present, citing the example of Vitamin B12, Vitamin B6, Vitamin D, Vitamin C.


    "What are the incentives the government wants to give because I can't compete in pricing with China. So my whole idea on this system of older drugs not made in India is that the government must have a very pragmatic policy that even if China is cheaper we should still make in India. We have to be self-reliant and self-sufficient," he said.


    The Octogenarian launched the inspirational science programme with the Royal Society of Chemistry (RSC) in India and donated Rs 8.7 crore for the same.


    His inspirational chemistry programme in association with RSC which was launched in 2014, where we had donated Rs 8 crore, has helped deliver more than 1,000 training workshops to over 23,000 teachers between 2014 and the end of 2018, with more than 9,000 schools across the 26 states.


    Read Also: Bio-Thera partners with Cipla to market key cancer biosimilar


    He added that his next step with RSC is how to get in new technology into India to make some of the older drugs that are not presently being manufactured.

    bedaquilineCiplacompulsive licensing systemdrugsessential drugsHealthcareIndiamonopolyOctogenarianpragmatic policyRoyal Society of ChemistryRSCTBTB Bedaquilinevitamin B12Vitamin B6Vitamin CVitamin DY K HamiedVitamin DY K Hamied
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok